Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL.
- Published in:
- Cancer Gene Therapy, 2012, v. 19, n. 1, p. 49, doi. 10.1038/cgt.2011.67
- By:
- Publication type:
- Article
Works matching IS 09291903 AND DT 2012 AND VI 19 AND IP 1
Results: 7
1
2
Fibroblast growth factor and ornithine decarboxylase 5′UTRs enable preferential expression in human prostate cancer cells and in prostate tumors of PTEN<sup>−/−</sup> transgenic mice.
- Published in:
- Cancer Gene Therapy, 2012, v. 19, n. 1, p. 19, doi. 10.1038/cgt.2011.62
- By:
- Publication type:
- Article
3
The chicken chorioallantoic membrane tumor assay as model for qualitative testing of oncolytic adenoviruses.
- Published in:
- Cancer Gene Therapy, 2012, v. 19, n. 1, p. 58, doi. 10.1038/cgt.2011.68
- By:
- Publication type:
- Article
4
Molecular network pathways and functional analysis of tumor signatures associated with development of resistance to viral gene therapy.
- Published in:
- Cancer Gene Therapy, 2012, v. 19, n. 1, p. 38, doi. 10.1038/cgt.2011.64
- By:
- Publication type:
- Article
5
Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function.
- Published in:
- Cancer Gene Therapy, 2012, v. 19, n. 1, p. 30, doi. 10.1038/cgt.2011.63
- By:
- Publication type:
- Article
6
CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model.
- Published in:
- Cancer Gene Therapy, 2012, v. 19, n. 1, p. 69, doi. 10.1038/cgt.2011.69
- By:
- Publication type:
- Article
7
D-amino acid oxidase gene therapy sensitizes glioma cells to the antiglycolytic effect of 3-bromopyruvate.
- Published in:
- Cancer Gene Therapy, 2012, v. 19, n. 1, p. 1, doi. 10.1038/cgt.2011.59
- By:
- Publication type:
- Article